Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry
Pharmaceutical innovation is like gambling at roulette, only the stakes are higher. Considerably higher, since the most recent estimates put the costs of drug development at US$ 800 million to US$ 1 billion - per drug! This is equivalent to the price tag of the Empire State Building, when it was for...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
2004
|
| Ausgabe: | 1st ed. 2004 |
| Schlagworte: | |
| Online-Zugang: | BTU01 Volltext |
| Zusammenfassung: | Pharmaceutical innovation is like gambling at roulette, only the stakes are higher. Considerably higher, since the most recent estimates put the costs of drug development at US$ 800 million to US$ 1 billion - per drug! This is equivalent to the price tag of the Empire State Building, when it was for sale a few years ago. In 2001, the major US and European pharmaceutical companies invested more than US$ 30 billion in R&D, at a higher R&D to-sales ratio than virtually any other industry, including chemicals, auto mobiles, electronics, aerospace, and computers. Delivering a blockbuster drug is the Holy Grail for any pharmaceutical company. But in the last decade the rules of developing blockbusters seem to have changed. On the one hand, more sophisticated screening technolo gies, genetic engineering, and expanding networks with biotechnology companies increase the probability of commercial success. Critical success factors include the discovery phase and a stronger outside-in orientation in the early innovation phase. After the implosion of the high-tech stock mar ket, biotechnology and other technology-driven opportunities may have lost some of their attractiveness for big pharma: a pipeline of solid and predictable innovations seems to be the highest goal of most pharmaceuti cal companies again. On the other hand, despite significant investments in pipeline management and novel technologies, there is still no recipe for ensuring a blockbuster hit |
| Beschreibung: | 1 Online-Ressource (XI, 178 p) |
| ISBN: | 9783540247814 |
| DOI: | 10.1007/978-3-540-24781-4 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046874141 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 200828s2004 |||| o||u| ||||||eng d | ||
| 020 | |a 9783540247814 |9 978-3-540-24781-4 | ||
| 024 | 7 | |a 10.1007/978-3-540-24781-4 |2 doi | |
| 035 | |a (ZDB-2-SBE)978-3-540-24781-4 | ||
| 035 | |a (OCoLC)864037651 | ||
| 035 | |a (DE-599)BVBBV046874141 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-634 | ||
| 082 | 0 | |a 658.514 |2 23 | |
| 084 | |a QR 525 |0 (DE-625)142044: |2 rvk | ||
| 100 | 1 | |a Gassmann, Oliver |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Leading Pharmaceutical Innovation |b Trends and Drivers for Growth in the Pharmaceutical Industry |c by Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz |
| 250 | |a 1st ed. 2004 | ||
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 2004 | |
| 300 | |a 1 Online-Ressource (XI, 178 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a Pharmaceutical innovation is like gambling at roulette, only the stakes are higher. Considerably higher, since the most recent estimates put the costs of drug development at US$ 800 million to US$ 1 billion - per drug! This is equivalent to the price tag of the Empire State Building, when it was for sale a few years ago. In 2001, the major US and European pharmaceutical companies invested more than US$ 30 billion in R&D, at a higher R&D to-sales ratio than virtually any other industry, including chemicals, auto mobiles, electronics, aerospace, and computers. Delivering a blockbuster drug is the Holy Grail for any pharmaceutical company. But in the last decade the rules of developing blockbusters seem to have changed. On the one hand, more sophisticated screening technolo gies, genetic engineering, and expanding networks with biotechnology companies increase the probability of commercial success. Critical success factors include the discovery phase and a stronger outside-in orientation in the early innovation phase. After the implosion of the high-tech stock mar ket, biotechnology and other technology-driven opportunities may have lost some of their attractiveness for big pharma: a pipeline of solid and predictable innovations seems to be the highest goal of most pharmaceuti cal companies again. On the other hand, despite significant investments in pipeline management and novel technologies, there is still no recipe for ensuring a blockbuster hit | ||
| 650 | 4 | |a Innovation/Technology Management | |
| 650 | 4 | |a Pharmacy | |
| 650 | 4 | |a Public Health | |
| 650 | 4 | |a R & D/Technology Policy | |
| 650 | 4 | |a Management | |
| 650 | 4 | |a Industrial management | |
| 650 | 4 | |a Pharmacy | |
| 650 | 4 | |a Public health | |
| 650 | 4 | |a Economic policy | |
| 650 | 0 | 7 | |a Arzneimittelmarkt |0 (DE-588)4003131-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Erfolgsfaktor |0 (DE-588)4197034-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Innovationsmanagement |0 (DE-588)4161817-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Innovationswettbewerb |0 (DE-588)4192032-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Marktentwicklung |0 (DE-588)4123713-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 0 | 1 | |a Innovationsmanagement |0 (DE-588)4161817-8 |D s |
| 689 | 0 | 2 | |a Erfolgsfaktor |0 (DE-588)4197034-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Arzneimittelmarkt |0 (DE-588)4003131-7 |D s |
| 689 | 1 | 1 | |a Innovationswettbewerb |0 (DE-588)4192032-6 |D s |
| 689 | 1 | 2 | |a Marktentwicklung |0 (DE-588)4123713-4 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Reepmeyer, Gerrit |4 aut | |
| 700 | 1 | |a von Zedtwitz, Maximilian |4 aut | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783662122198 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783662122181 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540407171 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-540-24781-4 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SBE |a ZDB-2-BAE | ||
| 940 | 1 | |q ZDB-2-SBE_Archiv | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032284273 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-540-24781-4 |l BTU01 |p ZDB-2-SBE |q ZDB-2-SBE_Archiv |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804181725164601344 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Gassmann, Oliver Reepmeyer, Gerrit von Zedtwitz, Maximilian |
| author_facet | Gassmann, Oliver Reepmeyer, Gerrit von Zedtwitz, Maximilian |
| author_role | aut aut aut |
| author_sort | Gassmann, Oliver |
| author_variant | o g og g r gr z m v zm zmv |
| building | Verbundindex |
| bvnumber | BV046874141 |
| classification_rvk | QR 525 |
| collection | ZDB-2-SBE ZDB-2-BAE |
| ctrlnum | (ZDB-2-SBE)978-3-540-24781-4 (OCoLC)864037651 (DE-599)BVBBV046874141 |
| dewey-full | 658.514 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 658 - General management |
| dewey-raw | 658.514 |
| dewey-search | 658.514 |
| dewey-sort | 3658.514 |
| dewey-tens | 650 - Management and auxiliary services |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1007/978-3-540-24781-4 |
| edition | 1st ed. 2004 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04227nmm a2200709zc 4500</leader><controlfield tag="001">BV046874141</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">200828s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783540247814</subfield><subfield code="9">978-3-540-24781-4</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-540-24781-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBE)978-3-540-24781-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)864037651</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046874141</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-634</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">658.514</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QR 525</subfield><subfield code="0">(DE-625)142044:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gassmann, Oliver</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Leading Pharmaceutical Innovation</subfield><subfield code="b">Trends and Drivers for Growth in the Pharmaceutical Industry</subfield><subfield code="c">by Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2004</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XI, 178 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pharmaceutical innovation is like gambling at roulette, only the stakes are higher. Considerably higher, since the most recent estimates put the costs of drug development at US$ 800 million to US$ 1 billion - per drug! This is equivalent to the price tag of the Empire State Building, when it was for sale a few years ago. In 2001, the major US and European pharmaceutical companies invested more than US$ 30 billion in R&D, at a higher R&D to-sales ratio than virtually any other industry, including chemicals, auto mobiles, electronics, aerospace, and computers. Delivering a blockbuster drug is the Holy Grail for any pharmaceutical company. But in the last decade the rules of developing blockbusters seem to have changed. On the one hand, more sophisticated screening technolo gies, genetic engineering, and expanding networks with biotechnology companies increase the probability of commercial success. Critical success factors include the discovery phase and a stronger outside-in orientation in the early innovation phase. After the implosion of the high-tech stock mar ket, biotechnology and other technology-driven opportunities may have lost some of their attractiveness for big pharma: a pipeline of solid and predictable innovations seems to be the highest goal of most pharmaceuti cal companies again. On the other hand, despite significant investments in pipeline management and novel technologies, there is still no recipe for ensuring a blockbuster hit</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Innovation/Technology Management</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Public Health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">R & D/Technology Policy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Management</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industrial management</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Public health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Economic policy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelmarkt</subfield><subfield code="0">(DE-588)4003131-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Erfolgsfaktor</subfield><subfield code="0">(DE-588)4197034-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Innovationsmanagement</subfield><subfield code="0">(DE-588)4161817-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Innovationswettbewerb</subfield><subfield code="0">(DE-588)4192032-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Marktentwicklung</subfield><subfield code="0">(DE-588)4123713-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Innovationsmanagement</subfield><subfield code="0">(DE-588)4161817-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Erfolgsfaktor</subfield><subfield code="0">(DE-588)4197034-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Arzneimittelmarkt</subfield><subfield code="0">(DE-588)4003131-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Innovationswettbewerb</subfield><subfield code="0">(DE-588)4192032-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Marktentwicklung</subfield><subfield code="0">(DE-588)4123713-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reepmeyer, Gerrit</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">von Zedtwitz, Maximilian</subfield><subfield code="4">aut</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783662122198</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783662122181</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540407171</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-540-24781-4</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBE</subfield><subfield code="a">ZDB-2-BAE</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBE_Archiv</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032284273</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-540-24781-4</subfield><subfield code="l">BTU01</subfield><subfield code="p">ZDB-2-SBE</subfield><subfield code="q">ZDB-2-SBE_Archiv</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046874141 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T15:15:40Z |
| indexdate | 2024-07-10T08:56:13Z |
| institution | BVB |
| isbn | 9783540247814 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032284273 |
| oclc_num | 864037651 |
| open_access_boolean | |
| owner | DE-634 |
| owner_facet | DE-634 |
| physical | 1 Online-Ressource (XI, 178 p) |
| psigel | ZDB-2-SBE ZDB-2-BAE ZDB-2-SBE_Archiv ZDB-2-SBE ZDB-2-SBE_Archiv |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| spelling | Gassmann, Oliver Verfasser aut Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry by Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz 1st ed. 2004 Berlin, Heidelberg Springer Berlin Heidelberg 2004 1 Online-Ressource (XI, 178 p) txt rdacontent c rdamedia cr rdacarrier Pharmaceutical innovation is like gambling at roulette, only the stakes are higher. Considerably higher, since the most recent estimates put the costs of drug development at US$ 800 million to US$ 1 billion - per drug! This is equivalent to the price tag of the Empire State Building, when it was for sale a few years ago. In 2001, the major US and European pharmaceutical companies invested more than US$ 30 billion in R&D, at a higher R&D to-sales ratio than virtually any other industry, including chemicals, auto mobiles, electronics, aerospace, and computers. Delivering a blockbuster drug is the Holy Grail for any pharmaceutical company. But in the last decade the rules of developing blockbusters seem to have changed. On the one hand, more sophisticated screening technolo gies, genetic engineering, and expanding networks with biotechnology companies increase the probability of commercial success. Critical success factors include the discovery phase and a stronger outside-in orientation in the early innovation phase. After the implosion of the high-tech stock mar ket, biotechnology and other technology-driven opportunities may have lost some of their attractiveness for big pharma: a pipeline of solid and predictable innovations seems to be the highest goal of most pharmaceuti cal companies again. On the other hand, despite significant investments in pipeline management and novel technologies, there is still no recipe for ensuring a blockbuster hit Innovation/Technology Management Pharmacy Public Health R & D/Technology Policy Management Industrial management Public health Economic policy Arzneimittelmarkt (DE-588)4003131-7 gnd rswk-swf Erfolgsfaktor (DE-588)4197034-2 gnd rswk-swf Innovationsmanagement (DE-588)4161817-8 gnd rswk-swf Innovationswettbewerb (DE-588)4192032-6 gnd rswk-swf Marktentwicklung (DE-588)4123713-4 gnd rswk-swf Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf Pharmazeutische Industrie (DE-588)4045696-1 s Innovationsmanagement (DE-588)4161817-8 s Erfolgsfaktor (DE-588)4197034-2 s DE-604 Arzneimittelmarkt (DE-588)4003131-7 s Innovationswettbewerb (DE-588)4192032-6 s Marktentwicklung (DE-588)4123713-4 s Reepmeyer, Gerrit aut von Zedtwitz, Maximilian aut Erscheint auch als Druck-Ausgabe 9783662122198 Erscheint auch als Druck-Ausgabe 9783662122181 Erscheint auch als Druck-Ausgabe 9783540407171 https://doi.org/10.1007/978-3-540-24781-4 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Gassmann, Oliver Reepmeyer, Gerrit von Zedtwitz, Maximilian Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry Innovation/Technology Management Pharmacy Public Health R & D/Technology Policy Management Industrial management Public health Economic policy Arzneimittelmarkt (DE-588)4003131-7 gnd Erfolgsfaktor (DE-588)4197034-2 gnd Innovationsmanagement (DE-588)4161817-8 gnd Innovationswettbewerb (DE-588)4192032-6 gnd Marktentwicklung (DE-588)4123713-4 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd |
| subject_GND | (DE-588)4003131-7 (DE-588)4197034-2 (DE-588)4161817-8 (DE-588)4192032-6 (DE-588)4123713-4 (DE-588)4045696-1 |
| title | Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry |
| title_auth | Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry |
| title_exact_search | Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry |
| title_exact_search_txtP | Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry |
| title_full | Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry by Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz |
| title_fullStr | Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry by Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz |
| title_full_unstemmed | Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry by Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz |
| title_short | Leading Pharmaceutical Innovation |
| title_sort | leading pharmaceutical innovation trends and drivers for growth in the pharmaceutical industry |
| title_sub | Trends and Drivers for Growth in the Pharmaceutical Industry |
| topic | Innovation/Technology Management Pharmacy Public Health R & D/Technology Policy Management Industrial management Public health Economic policy Arzneimittelmarkt (DE-588)4003131-7 gnd Erfolgsfaktor (DE-588)4197034-2 gnd Innovationsmanagement (DE-588)4161817-8 gnd Innovationswettbewerb (DE-588)4192032-6 gnd Marktentwicklung (DE-588)4123713-4 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd |
| topic_facet | Innovation/Technology Management Pharmacy Public Health R & D/Technology Policy Management Industrial management Public health Economic policy Arzneimittelmarkt Erfolgsfaktor Innovationsmanagement Innovationswettbewerb Marktentwicklung Pharmazeutische Industrie |
| url | https://doi.org/10.1007/978-3-540-24781-4 |
| work_keys_str_mv | AT gassmannoliver leadingpharmaceuticalinnovationtrendsanddriversforgrowthinthepharmaceuticalindustry AT reepmeyergerrit leadingpharmaceuticalinnovationtrendsanddriversforgrowthinthepharmaceuticalindustry AT vonzedtwitzmaximilian leadingpharmaceuticalinnovationtrendsanddriversforgrowthinthepharmaceuticalindustry |